IL6 and cancer: Seeking for selective glycan inhibitors that could target the proinflammatory activity of Gal-4 (66), we further studied the ability of BGA6 to interrupt Gal-4-driven production of IL-6, a central proinflammatory cytokine implicated in autoimmunity, infection, and cancer (67).